Mismatch for the minor histocompatibility antigen HA-2 and GVHD occurrence in HLA-A*0201-positive tunisian recipients of HSCs

Mohamed Hichem Sellami, Lamia Torjemane, Alejandro Espadas De Arias, Houda Kaabi, Saloua Ladeb, Tarek Ben Othman, Francesca Poli, Slama Hmida

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Graft-versus-Host disease (GVHD) has been widely linked to immunogenetic causes such as disparity between the recipient and its HLA geno-identical donor for some Non-HLA antigens called minor histocompatibility antigens (MiHAgs). HA-2 is one of potential human MiHAgs but its effect on the GVHD occurrence remains not clear. In order to examine such association in the Tunisian cohort of HSCs recipients, we performed a retrospective study on patients who received an HLA-identical HSCT between 2000 and 2009. The study was performed on 60 HLA-A2-positive patients who had received a haematopoietic stem cell transplant from an HLA-identical sibling. All patients received cyclosporine A andor methotrexate for GVHD prophylaxis. HA-2 genotyping assay was performed with SSP-PCR method and HLA-A*0201 positive samples were identified mainly with Luminex HLA-Typing method. Luminex HLA-Typing assay showed that only 53 cases were positives for the HLA-A*0201 allele. Among these cases, only 3 pairs were mismatched for the MiHAg HA-2. Acute GVHD occurred in 01 HA-2-mismatched pair while chronic GVHD was detected in 02 disparate couples. Univariate and multivariate analyses showed that MiHAg HA-2 disparity does not have any significant effect on the occurrence of either acute or chronic GVHD. This last one appeared to be correlated only with the age of patient (adulthood) (p: 0.011, OR: 22.092). Our findings support the previously reported data denying the influence of the HA-2 disparity on the GVHD occurrence after HSCT.

Original languageEnglish
Pages (from-to)611-620
Number of pages10
JournalImmunological Investigations
Volume39
Issue number6
DOIs
Publication statusPublished - 2010

Fingerprint

Minor Histocompatibility Antigens
Graft vs Host Disease
Histocompatibility Testing
HLA-A2 Antigen
Immunogenetics
Hematopoietic Stem Cells
HLA-A*02:01 antigen
Methotrexate
Cyclosporine
Siblings
Multivariate Analysis
Retrospective Studies
Alleles
Tissue Donors
Transplants
Antigens
Polymerase Chain Reaction

Keywords

  • Graft-vs-Host disease
  • HA-2
  • Haematopoietic Stem Cells Transplantation
  • HLA-A*0201
  • Minor histocompatibility antigens
  • Tunisian population

ASJC Scopus subject areas

  • Immunology

Cite this

Mismatch for the minor histocompatibility antigen HA-2 and GVHD occurrence in HLA-A*0201-positive tunisian recipients of HSCs. / Sellami, Mohamed Hichem; Torjemane, Lamia; De Arias, Alejandro Espadas; Kaabi, Houda; Ladeb, Saloua; Ben Othman, Tarek; Poli, Francesca; Hmida, Slama.

In: Immunological Investigations, Vol. 39, No. 6, 2010, p. 611-620.

Research output: Contribution to journalArticle

Sellami, Mohamed Hichem ; Torjemane, Lamia ; De Arias, Alejandro Espadas ; Kaabi, Houda ; Ladeb, Saloua ; Ben Othman, Tarek ; Poli, Francesca ; Hmida, Slama. / Mismatch for the minor histocompatibility antigen HA-2 and GVHD occurrence in HLA-A*0201-positive tunisian recipients of HSCs. In: Immunological Investigations. 2010 ; Vol. 39, No. 6. pp. 611-620.
@article{8f1143aba3b841c6a243c42c0e4aa7fc,
title = "Mismatch for the minor histocompatibility antigen HA-2 and GVHD occurrence in HLA-A*0201-positive tunisian recipients of HSCs",
abstract = "Graft-versus-Host disease (GVHD) has been widely linked to immunogenetic causes such as disparity between the recipient and its HLA geno-identical donor for some Non-HLA antigens called minor histocompatibility antigens (MiHAgs). HA-2 is one of potential human MiHAgs but its effect on the GVHD occurrence remains not clear. In order to examine such association in the Tunisian cohort of HSCs recipients, we performed a retrospective study on patients who received an HLA-identical HSCT between 2000 and 2009. The study was performed on 60 HLA-A2-positive patients who had received a haematopoietic stem cell transplant from an HLA-identical sibling. All patients received cyclosporine A andor methotrexate for GVHD prophylaxis. HA-2 genotyping assay was performed with SSP-PCR method and HLA-A*0201 positive samples were identified mainly with Luminex HLA-Typing method. Luminex HLA-Typing assay showed that only 53 cases were positives for the HLA-A*0201 allele. Among these cases, only 3 pairs were mismatched for the MiHAg HA-2. Acute GVHD occurred in 01 HA-2-mismatched pair while chronic GVHD was detected in 02 disparate couples. Univariate and multivariate analyses showed that MiHAg HA-2 disparity does not have any significant effect on the occurrence of either acute or chronic GVHD. This last one appeared to be correlated only with the age of patient (adulthood) (p: 0.011, OR: 22.092). Our findings support the previously reported data denying the influence of the HA-2 disparity on the GVHD occurrence after HSCT.",
keywords = "Graft-vs-Host disease, HA-2, Haematopoietic Stem Cells Transplantation, HLA-A*0201, Minor histocompatibility antigens, Tunisian population",
author = "Sellami, {Mohamed Hichem} and Lamia Torjemane and {De Arias}, {Alejandro Espadas} and Houda Kaabi and Saloua Ladeb and {Ben Othman}, Tarek and Francesca Poli and Slama Hmida",
year = "2010",
doi = "10.3109/08820131003775029",
language = "English",
volume = "39",
pages = "611--620",
journal = "Immunological Investigations",
issn = "0882-0139",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Mismatch for the minor histocompatibility antigen HA-2 and GVHD occurrence in HLA-A*0201-positive tunisian recipients of HSCs

AU - Sellami, Mohamed Hichem

AU - Torjemane, Lamia

AU - De Arias, Alejandro Espadas

AU - Kaabi, Houda

AU - Ladeb, Saloua

AU - Ben Othman, Tarek

AU - Poli, Francesca

AU - Hmida, Slama

PY - 2010

Y1 - 2010

N2 - Graft-versus-Host disease (GVHD) has been widely linked to immunogenetic causes such as disparity between the recipient and its HLA geno-identical donor for some Non-HLA antigens called minor histocompatibility antigens (MiHAgs). HA-2 is one of potential human MiHAgs but its effect on the GVHD occurrence remains not clear. In order to examine such association in the Tunisian cohort of HSCs recipients, we performed a retrospective study on patients who received an HLA-identical HSCT between 2000 and 2009. The study was performed on 60 HLA-A2-positive patients who had received a haematopoietic stem cell transplant from an HLA-identical sibling. All patients received cyclosporine A andor methotrexate for GVHD prophylaxis. HA-2 genotyping assay was performed with SSP-PCR method and HLA-A*0201 positive samples were identified mainly with Luminex HLA-Typing method. Luminex HLA-Typing assay showed that only 53 cases were positives for the HLA-A*0201 allele. Among these cases, only 3 pairs were mismatched for the MiHAg HA-2. Acute GVHD occurred in 01 HA-2-mismatched pair while chronic GVHD was detected in 02 disparate couples. Univariate and multivariate analyses showed that MiHAg HA-2 disparity does not have any significant effect on the occurrence of either acute or chronic GVHD. This last one appeared to be correlated only with the age of patient (adulthood) (p: 0.011, OR: 22.092). Our findings support the previously reported data denying the influence of the HA-2 disparity on the GVHD occurrence after HSCT.

AB - Graft-versus-Host disease (GVHD) has been widely linked to immunogenetic causes such as disparity between the recipient and its HLA geno-identical donor for some Non-HLA antigens called minor histocompatibility antigens (MiHAgs). HA-2 is one of potential human MiHAgs but its effect on the GVHD occurrence remains not clear. In order to examine such association in the Tunisian cohort of HSCs recipients, we performed a retrospective study on patients who received an HLA-identical HSCT between 2000 and 2009. The study was performed on 60 HLA-A2-positive patients who had received a haematopoietic stem cell transplant from an HLA-identical sibling. All patients received cyclosporine A andor methotrexate for GVHD prophylaxis. HA-2 genotyping assay was performed with SSP-PCR method and HLA-A*0201 positive samples were identified mainly with Luminex HLA-Typing method. Luminex HLA-Typing assay showed that only 53 cases were positives for the HLA-A*0201 allele. Among these cases, only 3 pairs were mismatched for the MiHAg HA-2. Acute GVHD occurred in 01 HA-2-mismatched pair while chronic GVHD was detected in 02 disparate couples. Univariate and multivariate analyses showed that MiHAg HA-2 disparity does not have any significant effect on the occurrence of either acute or chronic GVHD. This last one appeared to be correlated only with the age of patient (adulthood) (p: 0.011, OR: 22.092). Our findings support the previously reported data denying the influence of the HA-2 disparity on the GVHD occurrence after HSCT.

KW - Graft-vs-Host disease

KW - HA-2

KW - Haematopoietic Stem Cells Transplantation

KW - HLA-A0201

KW - Minor histocompatibility antigens

KW - Tunisian population

UR - http://www.scopus.com/inward/record.url?scp=77954975773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954975773&partnerID=8YFLogxK

U2 - 10.3109/08820131003775029

DO - 10.3109/08820131003775029

M3 - Article

C2 - 20653428

AN - SCOPUS:77954975773

VL - 39

SP - 611

EP - 620

JO - Immunological Investigations

JF - Immunological Investigations

SN - 0882-0139

IS - 6

ER -